HC Wainwright Reiterates “$3.00” Price Target for Biopharmx Corp (BPMX)
A number of other brokerages also recently issued reports on BPMX. Maxim Group reissued a buy rating and set a $3.00 price objective on shares of Biopharmx Corp in a research report on Friday, June 2nd. Roth Capital set a $3.00 price objective on shares of Biopharmx Corp and gave the company a buy rating in a research report on Thursday, May 4th.
Shares of Biopharmx Corp (NASDAQ BPMX) opened at 0.47 on Thursday. The stock’s 50 day moving average is $0.55 and its 200 day moving average is $0.51. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22. The firm’s market capitalization is $31.80 million.
Biopharmx Corp (NASDAQ:BPMX) last issued its quarterly earnings data on Tuesday, June 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.07). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts forecast that Biopharmx Corp will post ($0.31) EPS for the current year.
In related news, major shareholder Vivo Capital Fund Viii, L.P. acquired 1,282,052 shares of Biopharmx Corp stock in a transaction on Friday, April 28th. The shares were acquired at an average cost of $0.78 per share, with a total value of $1,000,000.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
An institutional investor recently raised its position in Biopharmx Corp stock. Vanguard Group Inc. raised its position in Biopharmx Corp (NASDAQ:BPMX) by 71.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 455,409 shares of the company’s stock after buying an additional 190,524 shares during the period. Vanguard Group Inc. owned approximately 0.67% of Biopharmx Corp worth $230,000 as of its most recent filing with the SEC.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.